Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution

被引:104
作者
Wasser, K
Klein, SK
Fink, C
Junkermann, H
Sinn, HP
Zuna, I
Knopp, MV
Delorme, S
机构
[1] German Canc Res Ctr, Dept Oncol Diagnost & Therapy, D-69120 Heidelberg, Germany
[2] Zentralkrankenhaus, D-28205 Bremen, Germany
[3] Univ Heidelberg, Dept Pathol, D-69120 Heidelberg, Germany
[4] Ohio State Univ, Univ Hosp, Dept Radiol, Columbus, OH 43210 USA
关键词
breast neoplasms; chemotherapy; MRI; follow-up studies;
D O I
10.1007/s00330-002-1654-1
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to evaluate changes in both size and contrast enhancement of breast tumors during neoadjuvant chemotherapy, using dynamic MRI with high temporal resolution. Patients with advanced breast cancer (n=21) underwent a 1.5-T MRI scan prior to and following neoadjuvant chemotherapy with four cycles. Dynamic contrast enhancement was measured using a fast turbo-FLASH sequence and quantified using a two-compartment model with the parameters k(ep) and amplitude. Image analysis was done on images overlayed with a color map of parameters. The correlation between tumor diameter measured by histopathology and MRI was 0.7 (p<0.003). A reduction of tumor size after chemotherapy of more than 25% was associated with a decrease of both analyzed contrast enhancement parameters (k(ep): p<0.002; amplitude: p<0.006), where k(ep) began to drop already after the first cycle of chemotherapy (p<0.008). A clear reduction of tumor size was only noted after the third cycle (p<0.008). In patients without tumor regression there was also a trend towards an early reduction of contrast enhancement. We assume that MRI with high temporal resolution and color mapping is a novel tool to assess therapeutic effects of neoadjuvant chemotherapy in breast tumors, which deserves further prospective evaluation.
引用
收藏
页码:80 / 87
页数:8
相关论文
共 38 条
[1]  
Abraham DC, 1996, CANCER, V78, P91, DOI 10.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO
[2]  
2-2
[3]   PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].
BONADONNA, G ;
VERONESI, U ;
BRAMBILLA, C ;
FERRARI, L ;
LUINI, A ;
GRECO, M ;
BARTOLI, C ;
DEYOLDI, GC ;
ZUCALI, R ;
RILKE, F ;
ANDREOLA, S ;
SILVESTRINI, R ;
DIFRONZO, G ;
VALAGUSSA, P .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545
[4]   Methods for quantitative assessment of tissue microcirculation using dynamic contrast-enhanced MR imaging [J].
Brix, G ;
Schreiber, W ;
Hoffmann, U ;
Guckel, F ;
Hawighorst, H ;
Knopp, MV .
RADIOLOGE, 1997, 37 (06) :470-480
[5]   PROBLEMS IN EVALUATING RESPONSE OF PRIMARY BREAST-CANCER TO SYSTEMIC THERAPY [J].
COCCONI, G ;
DIBLASIO, B ;
ALBERTI, G ;
BISAGNI, G ;
BOTTI, E ;
PERACCHIA, G .
BREAST CANCER RESEARCH AND TREATMENT, 1984, 4 (04) :309-313
[6]   Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography [J].
Davis, PL ;
Staiger, MJ ;
Harris, KB ;
Ganott, MA ;
Klementaviciene, J ;
McCarthy, KS ;
Tobon, H .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 37 (01) :1-9
[7]   Metronomic scheduling: the future of chemotherapy? [J].
Gasparini, G .
LANCET ONCOLOGY, 2001, 2 (12) :733-740
[8]   LOCAL ADVANCED BREAST-CANCER - CONTRAST-ENHANCED SUBTRACTION MR-IMAGING OF RESPONSE TO PREOPERATIVE CHEMOTHERAPY [J].
GILLES, R ;
GUINEBRETIERE, JM ;
TOUSSAINT, C ;
SPIELMAN, M ;
RIETJENS, M ;
PETIT, JY ;
CONTESSO, G ;
MASSELOT, J ;
VANEL, D .
RADIOLOGY, 1994, 191 (03) :633-638
[9]  
Hawighorst H, 1998, CLIN CANCER RES, V4, P2305
[10]   PHARMACOKINETIC ANALYSIS OF GD-DTPA ENHANCEMENT IN DYNAMIC MR OF BREAST-CARCINOMA [J].
HESS, T ;
KNOPP, MV ;
HOFFMANN, U ;
BRIX, G ;
JUNKERMANN, H ;
ZUNA, I ;
VONFOURNIER, D ;
VANKAICK, G .
FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NEUEN BILDGEBENDEN VERFAHREN, 1994, 160 (06) :518-523